A BILL 
To amend the Federal Trade Commission Act to prohibit 
product hopping, and for other purposes. 
Be it enacted by the Senate and House of Representa-
1
tives of the United States of America in Congress assembled, 
2
SECTION 1. SHORT TITLE. 
3
This Act may be cited as the ‘‘Affordable Prescrip-
4
tions for Patients Through Promoting Competition Act of 
5
2021’’. 
6
SEC. 2. PRODUCT HOPPING. 
7
(a) IN GENERAL.—The Federal Trade Commission 
8
Act (15 U.S.C. 41 et seq.) is amended by inserting after 
9
section 26 (15 U.S.C. 57c–2) the following: 
10
02:52 Jun 08, 2021
H2873
2 
•HR 2873 IH
‘‘SEC. 27. PRODUCT HOPPING. 
1
‘‘(a) DEFINITIONS.—In this section: 
2
‘‘(1) ABBREVIATED NEW DRUG APPLICATION.— 
3
The term ‘abbreviated new drug application’ means 
4
any application under subsection (j) of section 505 
5
of the Federal Food, Drug, and Cosmetic Act (21 
6
U.S.C. 355) or an application under subsection 
7
(b)(2) of such section 505 that seeks a therapeutic 
8
equivalence rating to the reference product. 
9
‘‘(2) BIOSIMILAR BIOLOGICAL PRODUCT.—The 
10
term ‘biosimilar biological product’ means a biologi-
11
cal product licensed under section 351(k) of the 
12
Public Health Service Act (42 U.S.C. 262(k)). 
13
‘‘(3) BIOSIMILAR
BIOLOGICAL
PRODUCT
LI-
14
CENSE APPLICATION.—The term ‘biosimilar biologi-
15
cal product license application’ means an application 
16
submitted under section 351(k) of the Public Health 
17
Service Act (42 U.S.C. 262(k)). 
18
‘‘(4) FOLLOW-ON PRODUCT.—The term ‘follow- 
19
on product’— 
20
‘‘(A) means a drug approved through an 
21
application or supplement to an application sub-
22
mitted under section 505(b) of the Federal 
23
Food, Drug, and Cosmetic Act (21 U.S.C. 
24
355(b)) or a biological product licensed through 
25
an application or supplement to an application 
26
02:52 Jun 08, 2021
H2873
3 
•HR 2873 IH
submitted under section 351(a) of the Public 
1
Health Service Act (42 U.S.C. 262(a)) for a 
2
change, modification, or reformulation to the 
3
same manufacturer’s previously approved drug 
4
or biological product that shares an indication, 
5
in whole or in part, with the same manufactur-
6
er’s previously approved drug or biological prod-
7
uct; and 
8
‘‘(B) excludes such an application or sup-
9
plement to an application for a change, modi-
10
fication, or reformulation of a drug or biological 
11
product that is requested by the Secretary or 
12
necessary to comply with law, including sections 
13
505A and 505B of the Federal Food, Drug, 
14
and Cosmetic Act (21 U.S.C. 355a, 355c). 
15
‘‘(5) GENERIC DRUG.—The term ‘generic drug’ 
16
means any drug approved under an application sub-
17
mitted under subsection (j) of section 505 of the 
18
Federal Food, Drug, and Cosmetic Act (21 U.S.C. 
19
355) or an application under subsection (b)(2) of 
20
such section 505 that seeks a therapeutic equiva-
21
lence rating to the reference product. 
22
‘‘(6) LISTED
DRUG.—The term ‘listed drug’ 
23
means a drug listed under section 505(j)(7) of the 
24
02:52 Jun 08, 2021
H2873
4 
•HR 2873 IH
Federal Food, Drug, and Cosmetic Act (21 U.S.C. 
1
355(j)(7)). 
2
‘‘(7) MANUFACTURER.—The term ‘manufac-
3
turer’ means the holder, licensee, or assignee of— 
4
‘‘(A) an approved application for a drug 
5
under section 505(c) of the Federal Food, 
6
Drug, and Cosmetic Act (21 U.S.C. 355(c)); or 
7
‘‘(B) a biological product license under sec-
8
tion 351(a) of the Public Health Service Act 
9
(42 U.S.C. 262(a)). 
10
‘‘(8) REFERENCE
PRODUCT.—The term ‘ref-
11
erence product’ has the meaning given the term in 
12
section 351(i) of the Public Health Service Act (42 
13
U.S.C. 262(i)). 
14
‘‘(9) ULTIMATE
PARENT
ENTITY.—The term 
15
‘ultimate parent entity’ has the meaning given the 
16
term in section 801.1 of title 16, Code of Federal 
17
Regulations, or any successor regulation. 
18
‘‘(b) PROHIBITION ON PRODUCT HOPPING.— 
19
‘‘(1) PRIMA FACIE.—A manufacturer of a ref-
20
erence product or listed drug shall be considered to 
21
have engaged in an unfair method of competition in 
22
or affecting commerce in violation of section 5(a) if 
23
complaint counsel or the Commission demonstrates 
24
in an action or proceeding initiated by the Commis-
25
02:52 Jun 08, 2021
H2873
5 
•HR 2873 IH
sion under subsection (c) that, during the period be-
1
ginning on the date on which the manufacturer of 
2
the reference product or listed drug first receives no-
3
tice that an applicant has submitted to the Commis-
4
sioner of Food and Drugs an abbreviated new drug 
5
application or biosimilar biological product license 
6
application referencing the reference product or list-
7
ed drug and ending on the date that is the earlier 
8
of 180 days after the date on which that generic 
9
drug or biosimilar biological product or another ge-
10
neric drug or biosimilar biological product ref-
11
erencing the listed drug or reference product is first 
12
marketed or 3 years after the date on which the fol-
13
low-on product is first marketed, the manufacturer 
14
engaged in either of the following actions: 
15
‘‘(A) The manufacturer engaged in a hard 
16
switch, which shall be established by dem-
17
onstrating that the manufacturer engaged in ei-
18
ther of the following actions: 
19
‘‘(i) Upon the request of the manufac-
20
turer of the listed drug or reference prod-
21
uct, the Commissioner of Food and Drugs 
22
withdrew the approval of the application 
23
for the listed drug or reference product or 
24
placed the listed drug or reference product 
25
02:52 Jun 08, 2021
H2873
6 
•HR 2873 IH
on the discontinued products list and the 
1
manufacturer marketed or sold a follow-on 
2
product. 
3
‘‘(ii) The manufacturer of the listed 
4
drug or reference product— 
5
‘‘(I)(aa) withdrew, discontinued 
6
the manufacture of, or announced 
7
withdrawal of, discontinuance of the 
8
manufacture of, or intent to withdraw 
9
the application with respect to the 
10
drug or reference product in a manner 
11
that impedes competition from a ge-
12
neric drug or a biosimilar biological 
13
product, which may be established by 
14
objective circumstances, unless such 
15
actions were taken by the manufac-
16
turer pursuant to a request of the 
17
Commissioner of Food and Drugs; or 
18
‘‘(bb) destroyed the inventory of 
19
the listed drug or reference product in 
20
a manner that impedes competition 
21
from a generic drug or a biosimilar bi-
22
ological product, which may be estab-
23
lished by objective circumstances; and 
24
02:52 Jun 08, 2021
H2873
7 
•HR 2873 IH
‘‘(II) marketed or sold a follow-on 
1
product. 
2
‘‘(B) The manufacturer engaged in a soft 
3
switch, which shall be established by dem-
4
onstrating that the manufacturer engaged in 
5
both of the following actions: 
6
‘‘(i) The manufacturer took actions 
7
with respect to the listed drug or reference 
8
product other than those described in sub-
9
paragraph (A) that unfairly disadvantage 
10
the listed drug or reference product rel-
11
ative to the follow-on product described in 
12
clause (ii) in a manner that impedes com-
13
petition from a generic drug or a bio-
14
similar biological product, which may be 
15
established by objective circumstances. 
16
‘‘(ii) The manufacturer marketed or 
17
sold a follow-on product. 
18
‘‘(2) EXCLUSIONS.—Nothing in this section 
19
shall prohibit actions that consist solely of— 
20
‘‘(A) truthful, non-misleading promotional 
21
marketing; or 
22
‘‘(B) ceasing promotional marketing for 
23
the listed drug or reference product. 
24
‘‘(3) JUSTIFICATION.— 
25
02:52 Jun 08, 2021
H2873
8 
•HR 2873 IH
‘‘(A) IN GENERAL.—Subject to paragraph 
1
(4), the actions described in paragraph (1) by 
2
a manufacturer of a listed drug or reference 
3
product shall not be considered to be an unfair 
4
method of competition in or affecting commerce 
5
if the manufacturer demonstrates to the Com-
6
mission or a district court of the United States, 
7
as applicable, in an action, suit or proceeding 
8
initiated by the Commission under subsection 
9
(c)(1) that— 
10
‘‘(i) the manufacturer would have 
11
taken the actions regardless of whether a 
12
generic drug that references the listed drug 
13
or biosimilar biological product that ref-
14
erences the reference product had already 
15
entered the market; and 
16
‘‘(ii)(I) with respect to a hard switch 
17
under paragraph (1)(A), the manufacturer 
18
took the action for reasons relating to the 
19
safety risk to patients of the listed drug or 
20
reference product; 
21
‘‘(II) with respect to an action de-
22
scribed 
in 
item 
(aa) 
of 
paragraph 
23
(1)(A)(ii)(I), there is a supply disruption 
24
that— 
25
02:52 Jun 08, 2021
H2873
9 
•HR 2873 IH
‘‘(aa) is outside of the control of 
1
the manufacturer; 
2
‘‘(bb) prevents the production or 
3
distribution of the applicable listed 
4
drug or reference product; and 
5
‘‘(cc) cannot be remedied by rea-
6
sonable efforts; or 
7
‘‘(III) with respect to a soft switch 
8
under paragraph (1)(B), the manufacturer 
9
had legitimate pro-competitive reasons, 
10
apart from the financial effects of reduced 
11
competition, to take the action. 
12
‘‘(B) RULE OF CONSTRUCTION.—Nothing 
13
in subparagraph (A) may be construed to limit 
14
the information that the Commission may oth-
15
erwise obtain in any proceeding or action insti-
16
tuted with respect to a violation of this section. 
17
‘‘(4) RESPONSE.—With respect to a justifica-
18
tion offered by a manufacturer under paragraph (3), 
19
the Commission may— 
20
‘‘(A) rebut any evidence presented by a 
21
manufacturer during that justification; or 
22
‘‘(B) establish by a preponderance of the 
23
evidence that— 
24
02:52 Jun 08, 2021
H2873
10 
•HR 2873 IH
‘‘(i) on balance, the pro-competitive 
1
benefits from the conduct described in sub-
2
paragraph (A) or (B) of paragraph (1), as 
3
applicable, do not outweigh any anti-
4
competitive effects of the conduct, even in 
5
consideration of the justification so offered; 
6
or 
7
‘‘(ii)(I) the conduct described in para-
8
graph (1) is not reasonably necessary to 
9
address or achieve the justifications de-
10
scribed in clause (ii) of paragraph (2)(A); 
11
or 
12
‘‘(II) the justifications described in 
13
clause (ii) of paragraph (2)(A) could be 
14
reasonably addressed or achieved through 
15
less anticompetitive means. 
16
‘‘(c) ENFORCEMENT.— 
17
‘‘(1) IN GENERAL.—If the Commission has rea-
18
son to believe that any manufacturer has violated, is 
19
violating, or is about to violate this section, or a rule 
20
promulgated under this section, the Commission 
21
may take any of the following actions: 
22
‘‘(A) Institute a proceeding under section 
23
5(b). 
24
02:52 Jun 08, 2021
H2873
11 
•HR 2873 IH
‘‘(B) In the same manner and to the same 
1
extent as provided in section 13(b), bring suit 
2
in a district court of the United States to tem-
3
porarily enjoin the action of the manufacturer. 
4
‘‘(C) Bring suit in a district court of the 
5
United States, in which the Commission may 
6
seek— 
7
‘‘(i) to permanently enjoin the action 
8
of the manufacturer; 
9
‘‘(ii) any of the remedies described in 
10
paragraph (3); and 
11
‘‘(iii) any other equitable remedy, in-
12
cluding ancillary equitable relief. 
13
‘‘(2) JUDICIAL REVIEW.— 
14
‘‘(A) IN GENERAL.—Notwithstanding any 
15
provision of section 5, any manufacturer that is 
16
subject to a final cease and desist order issued 
17
in a proceeding to enforce this section, or a rule 
18
promulgated under this section, may, not later 
19
than 30 days after the date on which the Com-
20
mission issues the order, petition for review of 
21
the order in— 
22
‘‘(i) the United States Court of Ap-
23
peals for the District of Columbia Circuit; 
24
or 
25
02:52 Jun 08, 2021
H2873
12 
•HR 2873 IH
‘‘(ii) the court of appeals of the 
1
United States for the circuit in which the 
2
ultimate parent entity of the manufacturer 
3
is incorporated. 
4
‘‘(B) TREATMENT OF FINDINGS.—In a re-
5
view of a final cease and desist order conducted 
6
by a court of appeals of the United States 
7
under subparagraph (A), the factual findings of 
8
the Commission shall be conclusive if those 
9
facts are supported by the evidence. 
10
‘‘(3) EQUITABLE REMEDIES.— 
11
‘‘(A) DISGORGEMENT.— 
12
‘‘(i) IN GENERAL.—In a suit brought 
13
under paragraph (1)(C), the Commission 
14
may seek, and the court may order, 
15
disgorgement of any unjust enrichment 
16
that a person obtained as a result of the 
17
violation that gives rise to the suit. 
18
‘‘(ii) 
CALCULATION.—Any 
19
disgorgement that is ordered with respect 
20
to a person under clause (i) shall be offset 
21
by any amount of restitution ordered 
22
under subparagraph (B). 
23
‘‘(iii) 
LIMITATIONS
PERIOD.—The 
24
Commission may seek disgorgement under 
25
02:52 Jun 08, 2021
H2873
13 
•HR 2873 IH
this subparagraph not later than 5 years 
1
after the latest date on which the person 
2
from which the disgorgement is sought re-
3
ceives any unjust enrichment from the ef-
4
fects of the violation that gives rise to the 
5
suit in which the Commission seeks the 
6
disgorgement. 
7
‘‘(B) RESTITUTION.— 
8
‘‘(i) IN GENERAL.—In a suit brought 
9
under paragraph (1)(C), the Commission 
10
may seek, and the court may order, res-
11
titution with respect to the violation that 
12
gives rise to the suit. 
13
‘‘(ii) 
LIMITATIONS
PERIOD.—The 
14
Commission may seek restitution under 
15
this subparagraph not later than 5 years 
16
after the latest date on which the person 
17
from which the restitution is sought re-
18
ceives any unjust enrichment from the ef-
19
fects of the violation that gives rise to the 
20
suit in which the Commission seeks the 
21
restitution. 
22
‘‘(4) RULES
OF
CONSTRUCTION.—Nothing in 
23
this subsection may be construed as— 
24
02:52 Jun 08, 2021
H2873
14 
•HR 2873 IH
‘‘(A) requiring the Commission to bring a 
1
suit seeking a temporary injunction under para-
2
graph (1)(B) before bringing a suit seeking a 
3
permanent injunction under paragraph (1)(C); 
4
or 
5
‘‘(B) affecting the authority of the Federal 
6
Trade Commission under any other provision of 
7
law.’’. 
8
(b) APPLICABILITY.—Section 27 of the Federal 
9
Trade Commission Act, as added by subsection (a), shall 
10
apply with respect to any— 
11
(1) conduct that occurs on or after the date of 
12
enactment of this Act; and 
13
(2) action or proceeding that is commenced on 
14
or after the date of enactment of this Act. 
15
(c) ANTITRUST LAWS.—Except to the extent sub-
16
section (a) establishes an additional basis for liability 
17
under the Federal Trade Commission Act (15 U.S.C. 41 
18
et seq.), nothing in this section, or the amendments made 
19
by this section, shall modify, impair, limit, or supersede 
20
the applicability of the antitrust laws as defined in sub-
21
section (a) of the first section of the Clayton Act (15 
22
U.S.C. 12(a)), and of section 5 of the Federal Trade Com-
23
mission Act (15 U.S.C. 45) to the extent that it applies 
24
to unfair methods of competition. 
25
02:52 Jun 08, 2021
H2873
15 
•HR 2873 IH
(d) RULEMAKING.—The Federal Trade Commission 
1
may issue rules under section 553 of title 5, United States 
2
Code, to carry out section 27 of the Federal Trade Com-
3
mission Act, as added by subsection (a), including by de-
4
fining any terms used in such section 27 (other than terms 
5
that are defined in subsection (a) of such section 27). 
6
Æ 
02:52 Jun 08, 2021
H2873
